$ABBV

The National Plan for Epilepsy Act (S494) establishes a national strategy for epilepsy research and care. This bill directs federal agencies to coordinate efforts, potentially increasing funding for research and treatment development, benefiting pharmaceutical and biotechnology companies focused on neurological disorders.

The PASTEUR Act establishes a subscription-style payment model for novel antibiotics, guaranteeing revenue for pharmaceutical companies developing new antimicrobial treatments. This de-risks R&D for antibiotics, driving investment and innovation in a critical healthcare area. Companies with strong antibiotic pipelines stand to gain significant, predictable revenue streams.

The PREEMIE Reauthorization Act of 2025 focuses on research and interventions for preterm birth. This bill provides continued, stable funding for existing programs, preventing a lapse in federal support for maternal and infant health initiatives. No new significant market opportunities are created, but existing beneficiaries maintain their revenue streams.

The Medicare for All Act, if enacted, eliminates private health insurance and significantly reduces revenue for pharmaceutical and medical device companies. This bill creates a single-payer system, shifting all healthcare spending to the federal government and directly impacting the profitability of current healthcare providers and insurers.